DPP-4 enzyme cleaves GLP-1 with a half-life of approximately 2 minutes, which is why early drug development focused on DPP-4 inhibitors and on engineering longer-lived GLP-1 analogs
Zepbound : This once-weekly weight loss injection contains tirzepatide, a dual GLP/GIP receptor agonist
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Detectable medication levels can linger for five to seven weeks after the last injection
The journal Food Quality and Preference published the study in March under the title Characteristics and food consumption for current, previous, and potential consumers of GPL-1s. Mention of product names does not imply endorsement by the University of Arkansas System Division of Agriculture
